8-K: STERIS Reports Strong Q3 FY26 Results, Maintains Outlook

STERIS plc announced robust financial results for its fiscal 2026 third quarter, with total revenue up 9% and adjusted EPS increasing to $2.53, while reaffirming its full-year outlook.

Summary

• Total revenue from continuing operations increased 9% to $1.5 billion for the third quarter of fiscal 2026, up from $1.4 billion in the prior year's third quarter.
• Constant currency organic revenue growth from continuing operations for the third quarter was 8%.
• As reported net income from continuing operations was $192.9 million, or $1.96 per diluted share, compared to $173.6 million, or $1.75 per diluted share, in Q3 FY25.
• Adjusted net income for the third quarter was $249.4 million, or $2.53 per diluted share, an increase from $229.1 million, or $2.32 per diluted share, in Q3 FY25.
• Net cash provided by operations for the first nine months of fiscal 2026 was $1.0 billion, compared with $887.3 million in the first nine months of fiscal 2025.
• Free cash flow for the first nine months of fiscal 2026 was $737.6 million, up from $588.1 million in the prior year period, driven by earnings growth and lower capital spending.
• The fiscal 2026 outlook was maintained, with expected as reported revenue growth of 8-9% and constant currency organic revenue growth of 7-8%.
• Adjusted earnings per diluted share from continuing operations for fiscal 2026 are expected to be in the range of $10.15 to $10.30.
• The negative impact of tariffs included in the fiscal 2026 outlook is now estimated to reduce pre-tax profit by approximately $55 million, an increase from prior expectations of $45 million.
• Capital expenditures are anticipated to be approximately $375 million, and free cash flow is expected to be approximately $850 million for fiscal 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong quarter with robust revenue and EPS growth, coupled with a maintained full-year outlook despite increased tariff headwinds, reflecting operational strength and effective management.

Positives

• Total revenue from continuing operations increased 9% to $1.5 billion in Q3 FY26.
• Constant currency organic revenue growth was strong at 8% for the quarter.
• As reported diluted EPS from continuing operations increased to $1.96 from $1.75 year-over-year.
• Adjusted diluted EPS from continuing operations increased to $2.53 from $2.32 year-over-year.
• Healthcare segment revenue grew 9%, reflecting 11% service, 8% consumable, and 7% capital equipment growth.
• Applied Sterilization Technologies (AST) revenue increased 11%, with 9% service and 103% capital equipment growth.
• Life Sciences revenue increased 7%, driven by 11% consumable and 7% capital equipment growth.
• Net cash provided by operations for the first nine months of fiscal 2026 increased to $1.0 billion from $887.3 million in the prior year.
• Free cash flow for the first nine months of fiscal 2026 significantly increased to $737.6 million from $588.1 million, primarily due to earnings growth and lower capital spending.
• The company maintained its fiscal 2026 outlook for revenue and adjusted EPS, indicating confidence in its performance despite headwinds.

Negatives

• Increased tariff headwinds are now estimated to reduce pre-tax profit by approximately $55 million for fiscal 2026, an increase from prior expectations of $45 million.
• Healthcare operating income was partially offset by tariff costs and inflation.
• Applied Sterilization Technologies (AST) operating income increase was partially offset by continued headwinds in labor and energy costs and unfavorable mix.
• Life Sciences operating income increase was partially offset by inflation and tariff costs.

Risks

• Operating costs, pressure on pricing (including inflation), customer loss, and business disruption (including difficulties in maintaining relationships with employees, customers, clients, or suppliers) being greater than expected and leading to erosion of profit margins.
• STERIS's ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses.
• Changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers.
• The possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the ethylene oxide litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS's performance, results, prospects or value.
• The potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations.
• The possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products.
• The possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS's businesses, industry or initiatives may adversely impact STERIS's performance, results, prospects or value.
• The impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments.
• The possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated.
• The level of STERIS's indebtedness limiting financial flexibility or increasing future borrowing costs.
• The effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS's Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed.
• The impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services.
• The effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions.
• The possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending.

Future Outlook

STERIS plc maintained its fiscal 2026 outlook, expecting as reported revenue from continuing operations to increase 8-9% and constant currency organic revenue growth of 7-8%. Adjusted earnings per diluted share from continuing operations are projected to be in the range of $10.15 to $10.30. The company anticipates capital expenditures of approximately $375 million and free cash flow of about $850 million, though tariff headwinds are now expected to reduce pre-tax profit by $55 million, an increase from previous estimates.

Management Comments

• "We are pleased with our performance in the third quarter." Dan Carestio, President and CEO of STERIS.
• "Our performance continues to benefit from strong execution by our commercial teams and our diversified portfolio." Dan Carestio, President and CEO of STERIS.
• "High single digit revenue growth combined with cost discipline is allowing us to deliver meaningful earnings per share growth despite increased tariff headwinds." Dan Carestio, President and CEO of STERIS.

Industry Context

StockSavvy.ai notes that STERIS's consistent high single-digit revenue growth and strong free cash flow generation in the healthcare and life sciences sectors demonstrate resilience and effective strategy execution, particularly in a period marked by inflationary pressures and increased tariff costs. The diversified portfolio, spanning infection prevention, sterilization technologies, and life science consumables, positions the company well against industry-specific demand fluctuations, aligning with broader trends of increasing healthcare infrastructure investment and biopharmaceutical R&D.

Legal Proceedings

• The company faces potential impacts from the outcome of any pending or threatened litigation, including the ethylene oxide litigation, which could delay, limit, or prevent new product or service introductions, impact production, supply, and/or marketing of existing products or services, result in uncovered costs, or otherwise affect performance, results, prospects, or value.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, and maintained positive outlook, potentially supporting share value and future dividends.
• Employees: Continued strong performance and growth could indicate job stability and potential for growth opportunities.
• Customers: Continued innovation and service growth in Healthcare and AST segments suggest ongoing value and support for patient care and infection prevention.
• Creditors: Improved cash flow and earnings strengthen the company's financial position, enhancing its ability to meet debt obligations.
• Suppliers: Stable and growing demand across segments implies continued business for suppliers, though cost discipline and inflation could impact negotiations.

Next Steps

• STERIS management will host a conference call on February 5, 2026, at 9:00 a.m. ET to discuss the results.
• A replay of the conference call will be available beginning at 12:00 p.m. ET on February 5, 2026.

Key Dates

Recommendation

The company delivered strong Q3 FY26 results with significant revenue and adjusted EPS growth, exceeding prior year performance. The maintained fiscal 2026 outlook, despite increased tariff headwinds, demonstrates management's confidence and operational resilience. Robust free cash flow generation further strengthens the financial position, making STERIS an attractive investment for long-term growth in the healthcare and life sciences sectors.

Keywords

STERIS, STE, Financial Results, Q3 2026, Earnings, Revenue Growth, EPS, Healthcare, Applied Sterilization Technologies, Life Sciences, Cash Flow, Outlook, Infection Prevention, Medical Devices, Pharmaceutical Services